SLAMF7 and Miyoshi myopathy: Recent advances in MM treatment, particularly the development of novel drugs such as proteasome inhibitors (PIs; bortezomib, carfilzomib, ixazomib), immunomodulatory drugs (IMiDs; thalidomide, lenalidomide, pomalidomide), and monoclonal antibodies (mAbs; daratumumab and isatuximab targeting CD38, and elotuzumab targeting SLAMF7), have greatly improved clinical outcomes.